Status:
UNKNOWN
Data Registry of Auto Immune Hemolytic Anemia
Lead Sponsor:
Sanquin Research & Blood Bank Divisions
Collaborating Sponsors:
Leiden University Medical Center
Radboud University Medical Center
Conditions:
Autoimmune Hemolytic Anemia
Eligibility:
All Genders
3+ years
Brief Summary
In autoimmune hemolytic anemia (AIHA) auto-antibodies directed against red blood cells (RBCs) lead to increased RBC clearance (hemolysis). This can result in a potentially life-threatening anemia. AIH...
Eligibility Criteria
Inclusion
- Sufficient comprehension of the Dutch language
- Signed informed consent by patient and/or parent/caretaker or donor
- Patients older than 3 months
- Patients with a positive DAT, a positive eluate and signs of hemolysis\*
- Patients with a positive DAT with complement only, negative eluate, but with signs of hemolysis
- Donors with a (repeatedly) positive DAT and a positive eluate and/or clinically relevant cold auto-antibodies
Exclusion
- Prior inclusion in the DRAIHA study
Key Trial Info
Start Date :
July 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
720 Patients enrolled
Trial Details
Trial ID
NCT04024202
Start Date
July 12 2019
End Date
December 1 2024
Last Update
July 19 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
AMC
Amsterdam-Zuidoost, Netherlands
2
UMC Radboud
Nijmegen, Netherlands